Phathom Pharmaceuticals (NASDAQ: PHAT) — Perfil da empresa, notícias e dados financeiros
Phathom Pharmaceuticals develops novel treatments for gastrointestinal diseases, focusing on innovative therapies for acid-related disorders.
Phathom Pharmaceuticals
Phathom Pharmaceuticals (NASDAQ:PHAT) is a biopharmaceutical company engaged in the development and commercialization of novel treatments for gastrointestinal diseases and disorders. The company focuses on creating better therapeutic options for patients suffering from conditions such as gastroesophageal reflux disease (GERD) and other related gastrointestinal (GI) diseases. Phathom Pharmaceuticals has been working on a portfolio of innovative drug candidates, including its lead project, a novel potassium-competitive acid blocker designed to provide an improved treatment alternative for acid-related disorders. With a dedicated team and a clear vision, the company aims to transform the current treatment landscape by addressing unmet medical needs and enhancing patient care in the GI therapeutic area.
Resumo
Operações
Produtos e/ou serviços de Phathom Pharmaceuticals
- Vonoprazan, a potent potassium-competitive acid blocker (P-CAB) for gastroesophageal reflux disease (GERD) and peptic ulcer disease.
- Development of new formulations of vonoprazan for improved delivery and efficacy.
- Partnerships for the distribution of vonoprazan in new markets, focusing on expanding global access.
- Research into additional indications for vonoprazan, exploring its potential in treating other gastrointestinal disorders.
- Collaborations on clinical trials to further establish the safety and efficiency profile of vonoprazan.
- Engagement in educational initiatives to raise awareness among healthcare professionals about the benefits of P-CABs.
equipe executiva do Phathom Pharmaceuticals
- Steven L. BastaCEO, President & Director
- David A. SocksCo-Founder
- Azmi NabulsiCo-Founder
- Sanjeev NarulaChief Financial & Business Officer
- Anne Marie CookChief Legal Officer & Corporate Secretary
- Jonathan BentleySenior VP and Head of Sales, Operations & Training
- Robert BreedloveVP of Finance & Principal Accounting Officer
- Eric SciorilliDirector of Business Development & Investor Relations
- Bill ApreaSenior VP, Chief Compliance Officer & Deputy Chief Legal Officer
- Nancy R. PhelanSenior Vice President of Marketing & Analytics
Últimas notícias sobre a Phathom Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Phathom Pharmaceuticals, em USD.
- Cap. de mercado
- 508,1 mi
- Receita (TTM)
- 239,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- -41.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 175,1 mi | -160 mi | -221,2 mi | |
| 55,3 mi | -277,5 mi | -334,3 mi | |
| 682 mil | -167,3 mi | -201,6 mi | |
| 0 | -172,4 mi | -197,7 mi |